Latest News for: aardvark

Edit

AARD DEADLINE NOTICE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Aardvark Therapeutics,

Hastings Tribune 12 Oct 2026
NEW YORK, Oct. 11, 2026 (GLOBE NEWSWIRE) -- ... .
Edit

AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law

Morgan Citizen 12 Oct 2026
("Aardvark" or "the Company") (NASDAQ.
Edit

Aardvark Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to ...

Morgan Citizen 12 Oct 2026
NEW YORK, Oct. 12, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Aardvark Therapeutics, Inc. ("Aardvark" or "the Company") (NASDAQ. AARD) violations of the federal securities laws ... .
Edit

Aardvark Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - AARD

PR Newswire 12 Oct 2026
12, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Aardvark Therapeutics, Inc. ("Aardvark" or "the Company") (NASDAQ ... Aardvark misled investors ...
Edit

URGENT AARDVARK DEADLINE: Bragar Eagel & Squire, P.C. Urges Aardvark Therapeutics, Inc.

Reflector 10 Oct 2026
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Aardvark (AARD) To Contact Him Directly To Discuss Their Options ... .
Edit

URGENT AARDVARK DEADLINE: Bragar Eagel & Squire, P.C. Urges Aardvark Therapeutics, Inc. Investors to Contact ...

The Daily Record - Dunn 10 Oct 2026
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Aardvark ....
Edit

Attention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Coastal

Hastings Tribune 10 Oct 2026
PHILADELPHIA, Oct. 10, 2026 (GLOBE NEWSWIRE) -- ... .
Edit

Aardvark Therapeutics, Inc. (AARD) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

PR Newswire 09 Oct 2026
Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Aardvark Therapeutics, Inc. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN AARDVARK THERAPEUTICS, INC ... Howard G ... Smith.
Edit

AARD DEADLINE ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Aardvark Therapeutics, Inc.

Enid News & Eagle 09 Oct 2026
NEW YORK, Oct. 08, 2026 (GLOBE NEWSWIRE) -- ... .
Edit

AARD DEADLINE ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel ...

Nasdaq Globe Newswire 09 Oct 2026
Rosen Law Firm, a global investor rights law firm, reminds purchasers of Aardvark Therapeutics, Inc.
Edit

Aardvark Therapeutics, Inc. (AARD) Investors with Substantial Losses Have Opportunity to Lead Aardvark Class Action Lawsuit

PR Newswire 08 Oct 2026
8, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP, a national shareholder rights firm, notifies investors in Aardvark Therapeutics, Inc ... Watch our video on the Aardvark investigation ... Aardvark's stock price fell another 32.1%.
Edit

AARDVARK THERAPEUTICS (NASDAQ: AARD) SECURITIES CLASS ACTION: ROSEN, A TOP RANKED LAW FIRM, Encourages Investors ...

Auburnpub dot com 08 Oct 2026
7, 2026 /PRNewswire/ -- AARDVARK THERAPEUTICS SECURITIES CLASS ACTION.
Edit

Aardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., MBA, to its Board of Directors

Nasdaq Globe Newswire 08 Oct 2026
Brings more than 25 years of experience in clinical strategy, biostatistics and regulatory submissions from Abivax, Alumis, MyoKardia and Genentech/Roche ... .
Edit

Attention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Coastal Financial Corporation (NASDAQ: CCB); Erasca, ...

Nasdaq Globe Newswire 08 Oct 2026
Aardvark Therapeutics (NASDAQ. AARD); Coastal Financial Corp. (NASDAQ. CCB); Erasca, Inc. (NASDAQ. ERAS); and New Era Energy & Digital, Inc. (NASDAQ. NUAI) ... .
Edit

Aardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., MBA, to its

The Eagle-Tribune 08 Oct 2026
Brings more than 25 years of experience in clinical strategy, biostatistics and regulatory submissions from Abivax, Alumis, MyoKardia and Genentech/Roche ... .

Article Search

tools
×
×
×
×